Predicted banana distribution map (2016) using logistic regression model M2-12 fitted using 12 covariates and significant two-way combinations. by Dennis Ochola (11626912)

Subjects:

Aggregated agroecological zones of Uganda (adapted from Wortmann & Eledu, 1999). by Dennis Ochola (11626912)

Subjects:

Velocity distribution at different openings (a) 25%; (b) 50%; (c) 75%; (d) 100%. by Weiqing Xu (1279959)

Decreased biofilm formation in the Δ<i>tad123</i> mutant cells. by Tra-My Duong-Nu (7300970)

Mean ± SD of the different parameters relative to bipedal stance on soft support with the eyes open recorded in the Chewing and Hand Grip groups. by Cristina Dolciotti (16317330)

M1-37T protein is degraded in a lysosome-independent manner, and its ubiquitination is not through K48 linkage. by Chenxi Wang (284364)

M1 protein harboring T37 is susceptible to ubiquitination at K187. by Chenxi Wang (284364)

Effect of the Hill coefficient on estimates of <i>ε</i>_max (left column) and IC₅₀ (right column) for the logistic model with drug applied to the growth rate <... by Hope Murphy (8843516)

Partial correlation of <i>ε</i>_max (left column) and IC₅₀ (right column) estimates at 10 days and 20 days (first and second bar of each color, respectively) o... by Hope Murphy (8843516)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects: